Company: SHPH
Filing Date: 2025-02-27
Form Type: 424B3
Source: 0001493152-25-008474
Chunk: 56

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-27
Form: 424B3
Chunk 56
---
                                                 |

| ● | regulatory                                                                                                          
 authorities may require the addition of labeling statements, such as a “black box” warning or a contraindication;   |
| ● | we                                                                                                                  
 may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients; |
| ● | we                                                                                                                  
 could be sued and held liable for harm caused to patients;                                                          |
| ● | the                                                                                                                 
 product may become less competitive; and                                                                            |
| ● | our                                                                                                                 
 reputation.                                                                                                         |

Risks Related to our Common Stock

If we fail to comply with the continued listing requirements of The Nasdaq Stock Market, it could result in our common stock being delisted, which could adversely affect the market price and liquidity of our securities and could have other adverse effects.

On December 31, 2024, the Company received a letter from Nasdaq stating that for the 30 consecutive business day period between November 15, 2024 to December 30, 2024 the Company’s common stock had failed to maintain a Minimum Bid Price Requirement of $1.00 per share, as required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a grace period of 180 calendar days, or until June 30, 2025, to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days.

Pursuant the new Nadsaq Rule 5810, which does not allow for more than one reverse split in any 12 month period, because Shuttle Pharma completed a 1-for-8 reverse stock split in August 2024, the Company must regain compliance with the Minimum Bid Price Requirement by no later than June 30, 2025, as the Company is not eligible for an additional 180-day compliance period. As a result, if the Company’s price per share does not organically increase to $1.00 or more prior to the end of May 2025, the Company will be obligated, upon obtaining stockholder approval, to complete a reverse split in order to regain compliance with the Nasdaq Listing Requirements. If the Company cannot regain compliance prior to June 30, 2025, Nasdaq will provide the Company with notice